Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Amgen (AMGN) Stock Price & Analysis
5,490 Followers
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$206.75 - $327.16
Previous Close$273.94
Volume2.32M
Average Volume (3M)2.93M
Market Cap
$144.69B
Enterprise Value$200.48B
Total Cash (Recent Filing)$10.94B
Total Debt (Recent Filing)$64.61B
Price to Earnings (P/E)21.9
Beta0.48
Next Earnings
May 02, 2024EPS Estimate
$3.88Next Dividend Ex-Date
May 16, 2024Dividend Yield3.13%
Share Statistics
EPS (TTM)12.48
Shares Outstanding535,918,901
10 Day Avg. Volume2,413,451
30 Day Avg. Volume2,926,724
Standard Deviation0.07
R-Squared0.17
Alpha0.00511
Financial Highlights & Ratios
Price to Book (P/B)-3.29
Price to Sales (P/S)5.21
Price to Cash Flow (P/CF)68.80
P/FCF Ratio33.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.11
Enterprise Value/Gross Profit10.16
Enterprise Value/Ebitda13.54
Forecast
1Y Price Target
$312.00Price Target Upside12.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyTezspire has demonstrated significant effectiveness in reducing COPD exacerbations, especially in patients with higher eosinophil counts, hinting at a strong position in the respiratory treatment market.
Patent SettlementSandoz's agreement to not launch a generic version of Prolia until February 2025 confirms the strength of the patent, ensuring market exclusivity for a longer period.
Pipeline DevelopmentAMGN's investment in expanding manufacturing facilities signals a commitment to growth and the ability to meet future demand for its promising drug pipeline.
Bears Say
Competitive PositionSafety concerns arise for MariTide with a high discontinuation rate and significant side effects like nausea and vomiting.
Drug EfficacyThe overall phase 2 trial for Tezspire missed the primary endpoint, which might raise concerns about its efficacy.
Financial Performance1Q earnings for AMGN could miss expectations with predicted ~2% revenue and ~6-7% EPS shortfall.
---
Ownership Overview
1.08% Insiders
21.42% Mutual Funds
30.08% Other Institutional Investors
47.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $206.75 and its highest was $327.16 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is May 02, 2024 which is today.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 06, 2024. The company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.591 by $0.119.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 3.13%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $3.88.
How many shares outstanding does Amgen have?
Amgen has 535,918,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.71 in its last earnings report, beating expectations of $4.591. Following the earnings report the stock price went down -6.39%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$312.00 (12.49% Upside)
$312.00 (12.49% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 219.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.10%
12-Months-Change
Fundamentals
Return on Equity
135.79%
Trailing 12-Months
Asset Growth
49.19%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q4 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Months Forecast
Average Price Target
$312.00
▲(12.49% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
22/27 ratings generated profit
1 Year Average Return
+15.26%
reiterated a buy rating 17 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 81.48% of your transactions generating a profit, with an average return of +15.26% per trade.
---